[image]

WFIRM's groundbreaking work in regenerative medicine is now in the national spotlight, driven by the NSF's Regional Innovation Engines (NSF Engines (https://new.nsf.gov/funding/initiatives/regional-innovation-engines)) competition. The NSF, an independent federal agency and a key driver for scientific advancements in the U.S. initiated this competition to foster tech-driven innovation ecosystems. Out of numerous contenders, 16 finalists remain, each selected for their potential to reshape key technology areas and address pressing societal challenges.

PHI is an integral part of the Regenerative Medicine Development Organization (ReMDO), located at WFIRM, which is committed to innovating Regenerative Medicine Clinical Manufacturing. PHI's collaboration with its valuable Alliance partners SAS, QIAGEN, and BioSpherix underscores the shared drive to revolutionize regenerative medicine. With PHI's biomedical engineer stationed at WFIRM, the partnership has made significant strides in running live cell experiments and collaborative efforts.

[image]

US PHI Inc. President Håkan Rosvall attended, upon invitation, an NSF meeting yesterday to support WFIRM's application for the government grant. He emphasizes the pivotal role of collaborations like that of PHI and WFIRM:

"It's exhilarating to see this great collaboration in regenerative medicine. The synergy between PHI, our dedicated ReMDO partners, and WFIRM showcases what's possible when innovators unite."

The NSF's competition is not merely about financial incentives. It represents a national effort to recognize organizations that can become giants in their respective industries, like Facebook or Tesla. Several of the 16 finalists will be announced this winter as the grant winners.